Vitamin D screening · falls risk

Vitamin D Screening: Who Has an Indication and What Falls Risk Adds

Vitamin D screening has an indication in malabsorption (inflammatory bowel disease, prior bowel surgery, celiac disease, post-bariatric anatomy), in darker skin at high latitude and in adiposity. Fall risk adds a documented balance baseline before any dosing schedule is chosen, because the harm signal in the dosing trials is falls.

Routine vitamin D testing is out of favor for the general population. Patients with malabsorption, dyslipidemia and fall risk were never the population that recommendation addressed.

Vitamin D screening in primary care has a clear guideline answer for the general population and almost none for the patients who generate the most questions. The 2024 Endocrine Society panel recommends against routine testing of 25-hydroxyvitamin D across the populations it reviewed, and against dosing above the dietary reference intake for disease prevention. Its scope statement is the operative line: it addresses people without an established indication.

In the video Vitamin D Is a Hormone, Not a Vitamin, Chapter 10 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, the argument is endocrine: a governed axis adapts to excess and punishes bolus dosing. For the physician the operational questions are narrower. Who has an indication, what distorts the value before interpretation, and why fall-risk assessment belongs in the same order set.

Is vitamin D screening necessary?

The systematic review behind the guideline screened 37,007 citations and retained 151 studies. It identified no trials of screening itself. The recommendation against testing therefore reflects a test-and-treat strategy that has never been trialed, not a negative trial of one. The same panel names four groups for empiric supplementation without testing (ages 1 to 18, adults over 75, pregnancy and high-risk prediabetes), prefers daily over intermittent high doses in adults over 50 with an indication, and concedes that optimal doses remain unclear.

That leaves the indicated patient to clinical judgment, which is exactly where a structured screen earns its place in the chart.

Who should be screened for vitamin D deficiency?

• Malabsorption. Across 25 observational studies and 5,826 patients with inflammatory bowel disease, active disease raised deficiency odds to 1.85, prior surgery to 1.61, biologic exposure to 1.78, and the Crohn’s phenotype to 1.38 relative to ulcerative colitis. Steroid exposure also carried 1.61. Short bowel, celiac disease and post-bariatric anatomy share the mechanism.
• Ancestry and latitude. Non-Caucasian ancestry carried an odds ratio of 3.79 in that same analysis, larger than any disease variable. Keeping 97.5% of dark-skinned adults at high latitude above 50 nmol/L in winter required 66.8 µg daily, roughly 2,672 IU, well above standard intake tables.
• Adiposity. Adipose tissue sequesters the molecule and lowers the circulating level, and BMI does not quantify the compartment responsible.
• Fall risk. Not an indication to supplement, but a reason to document balance status before a dosing schedule is chosen, because the harm signal in the dosing literature is falls.

How accurate is the vitamin D blood test?

Two error sources precede interpretation. Restandardization moved the American prevalence below 50 nmol/L from 22% to 31%, and the methods authors estimated that a single patient’s apparent level could range from 20 to 35 ng/mL by method. In the Canadian biobank comparison, the immunoassay carried an overall negative bias of 5.5 nmol/L against mass spectrometry, limits of agreement -23.8 to 12.7. The bias was 4.0 nmol/L below the non-HDL cholesterol threshold and 10.2 above it, and assay standardization did not eliminate it.

The consequence is directional. Dyslipidemic patients, the ones carrying insulin resistance and metaflammation, are biased toward a falsely low value, and the reference interval printed beside it was drawn from a largely indoor population. Recording the assay method with the value changes what a borderline number means and makes serial values comparable.

Can vitamin D dosing increase falls?

Trials that failed on benefit are informative on harm, and the harm concentrates in falls.

• Annual bolus. In 2,256 older women given 500,000 IU once a year, the fall rate was 83.4 versus 72.7 per 100 person-years, a rate ratio of 1.15, and fractures rose with a rate ratio of 1.26, the excess concentrated in the first three months after dosing. Median baseline was 49 nmol/L; fewer than 3% were below 25. These women were largely replete.
• Higher daily dose in fall-prone adults. Compared with 200 IU, 1000 IU or more yielded a hazard ratio of 1.87 for serious falls and 2.48 for falls requiring hospitalization, with no improvement in gait speed, grip strength, chair-stand performance or six-minute walk distance.
• Sustained high dose. Over three years, 10,000 IU daily reduced radial volumetric density by 7.5 mg HA/cm3 against 400 IU. Serum levels peaked at 188 nmol/L at three months and declined to 144.4 on an unchanged dose, consistent with catabolic adaptation. Bone strength did not differ.

For a practice, that moves fall prevention from a separate program into the vitamin D decision. A documented baseline from vestibular and balance testing, obtained before a schedule is set and repeated at reassessment, turns a trial signal into something observable in the individual patient. The pairing with cognition, which shares the same older population, is laid out in cognitive assessment and fall prevention.

Building vitamin D screening into workflow

An indication-driven order set is more defensible than either routine testing or none. One workable sequence:

1. Flag indications at intake: bowel resection, inflammatory bowel disease, celiac disease, bariatric surgery, chronic steroid or biologic exposure, darker skin at northern latitude, obesity.
2. Order the level with the metabolic blood work so the context from laboratory panels sits beside it, and record the assay method.
3. Add bioimpedance body composition where adiposity is part of the indication.
4. Document balance status before dosing and at reassessment.
5. Document schedule, daily rather than bolus, and a stop point once the deficit is corrected.

Measura [Cardiometabolic and Autonomic Health Analysis] measures and reports; the ordering physician interprets and manages. Protocolizing the screen is covered in standing orders for screening, and the documentation maps to the quality frameworks described in quality measures that cardiometabolic testing supports. The gastrointestinal patient who needs this screen often carries a second missed problem, addressed in screening IBD patients for spinal involvement. Full study data are in the Chapter 10 Deep Dive.

Frequently asked questions

Does the 2024 Endocrine Society guideline rule out vitamin D testing?

No. It suggests against routine testing in populations without an established indication, and its supporting review found no trials of screening in either direction. Patients with malabsorption, bowel resection, bariatric anatomy or chronic steroid exposure sit outside that scope. The panel still names four groups for empiric supplementation and prefers daily dosing over intermittent high doses. Patient selection is summarized in selection criteria.

Should immunoassay results be read differently in dyslipidemic patients?

Consider the direction of the bias. Against mass spectrometry, the immunoassay under-read by 10.2 nmol/L above the non-HDL cholesterol threshold and 4.0 nmol/L below it, and standardization did not remove the interference. A borderline value in a patient with high lipids may exaggerate deficiency. Recording the method keeps serial values comparable. Report structure is described in interpreting the report.

Is bolus vitamin D dosing appropriate in older adults?

The trial evidence argues against it. A single annual 500,000 IU dose increased falls and fractures in older women who were largely replete, with the excess clustered after dosing, and the guideline prefers daily over intermittent high doses in adults over 50. A large dose raises fibroblast growth factor 23, which suppresses activation and accelerates catabolism. Falls documentation within the wellness visit is outlined in annual wellness visit integration.

How does fall-risk assessment change vitamin D management?

It identifies the population in which dosing harm was measured. In fall-prone older adults, 1000 IU daily or more carried a hazard ratio of 1.87 for serious falls against 200 IU. A documented balance baseline lets you detect deterioration after a schedule change instead of inferring it after an injury. Reporting for falls-related screening is covered in MIPS and quality reporting.

Does correcting vitamin D treat inflammatory bowel disease?

Not on current evidence. Mendelian randomization in the Copenhagen and UK Biobank cohorts yielded a hazard ratio of 0.98 for Crohn’s disease and 1.01 for colitis, arguing against a causal role. Deficiency in these patients tracks disease activity, surgery and malabsorption, so correction addresses a real deficit rather than the bowel disease. The broader case for measuring terrain is in clinical rationale.

Why don’t doctors test vitamin D levels routinely?

Because the 2024 Endocrine Society guideline recommends against routine testing of 25-hydroxyvitamin D in people without an established indication. Its supporting review screened 37,007 citations and found no trials of screening itself, so the advice reflects a test-and-treat strategy that was never trialed. Patients with malabsorption, prior bowel or bariatric surgery, darker skin at high latitude or adiposity sit outside that scope.

What test is done to check vitamin D?

A blood level of 25-hydroxyvitamin D. A common method is immunoassay; mass spectrometry is the reference. In a Canadian biobank comparison the immunoassay read 5.5 nmol/L low overall, and lower still in patients above the non-HDL cholesterol threshold. Recording which method was used, alongside the value, makes a borderline number interpretable and keeps serial results comparable.

How often should vitamin D be checked?

The evidence here sets no fixed interval. Order the level when an indication is flagged at intake, together with the metabolic blood work, and record the assay method so repeat values compare. Once a daily schedule starts, reassess with the balance measurement repeated, and document a stop point for when the deficit is corrected, so testing follows a clinical decision rather than a habit.

References

• Demay, M. B., Pittas, A. G., Bikle, D. D., Diab, D. L., Kiely, M. E., Lazaretti-Castro, M., Lips, P., Mitchell, D. M., Murad, M. H., Powers, S., Rao, S. D., Scragg, R., Tayek, J. A., Valent, A. M., Walsh, J. M. E., & McCartney, C. R. (2024). Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 109(8), 1907–1947. https://doi.org/10.1210/clinem/dgae290
• Shah, V. P., Nayfeh, T., Alsawaf, Y., Saadi, S., Farah, M., Zhu, Y., Firwana, M., Seisa, M., Wang, Z., Scragg, R., Kiely, M. E., Lips, P., Mitchell, D. M., Demay, M. B., Pittas, A. G., & Murad, M. H. (2024). A systematic review supporting the Endocrine Society clinical practice guidelines on vitamin D. The Journal of Clinical Endocrinology and Metabolism, 109(8), 1961-1974. https://doi.org/10.1210/clinem/dgae312
• Shi, S., Feng, J., Zhou, L., Li, Y., & Shi, H. (2021). Risk factors for vitamin D deficiency in inflammatory bowel disease: A systematic review and meta-analysis. The Turkish Journal of Gastroenterology, 32(6), 508–518. https://doi.org/10.5152/tjg.2021.20614
• Cashman, K. D., Kiely, M. E., Andersen, R., Grønborg, I. M., Tetens, I., Tripkovic, L., Lanham-New, S. A., Lamberg-Allardt, C., Adebayo, F. A., Gallagher, J. C., Smith, L. M., Sacheck, J. M., Huang, Q., Ng, K., Yuan, C., Giovannucci, E. L., Rajakumar, K., Patel, S., Vanstone, C. A., … Weiler, H. A. (2022). Individual participant data (IPD)-level meta-analysis of randomised controlled trials to estimate the vitamin D dietary requirements in dark-skinned individuals resident at high latitude. European Journal of Nutrition, 61(2), 1015–1034. https://doi.org/10.1007/s00394-021-02699-6
• Binkley, N., Dawson-Hughes, B., Durazo-Arvizu, R., Thamm, M., Tian, L., Merkel, J. M., Jones, J. C., Carter, G. D., & Sempos, C. T. (2017). Vitamin D measurement standardization: The way out of the chaos. The Journal of Steroid Biochemistry and Molecular Biology, 173, 117–121. https://doi.org/10.1016/j.jsbmb.2016.12.002
• Weiler, H. A., Bielecki, A., Fu, W., Demonty, I., & Brooks, S. P. J. (2024). Cholesterol interference in the assessment of vitamin D status: A Canadian Health Measures Survey biobank project. The Journal of Nutrition, 154(5), 1676–1685. https://doi.org/10.1016/j.tjnut.2024.04.003
• Sanders, K. M., Stuart, A. L., Williamson, E. J., Simpson, J. A., Kotowicz, M. A., Young, D., & Nicholson, G. C. (2010). Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA, 303(18), 1815–1822. https://doi.org/10.1001/jama.2010.594
• Appel, L. J., Michos, E. D., Mitchell, C. M., Blackford, A. L., Sternberg, A. L., Miller, E. R., Juraschek, S. P., Schrack, J. A., Szanton, S. L., Charleston, J., Minotti, M., Baksh, S. N., Christenson, R. H., Shade, D. M., Shiferaw, W. F., Walston, J. D., Guralnik, J. M., Cai, T., & Tonascia, J. (2021). The effects of four doses of vitamin D supplements on falls in older adults: A response-adaptive, randomized clinical trial. Annals of Internal Medicine, 174(2), 145–156. https://doi.org/10.7326/M20-3812
• Burt, L. A., Billington, E. O., Rose, M. S., Raymond, D. A., Hanley, D. A., & Boyd, S. K. (2019). Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: A randomized clinical trial. JAMA, 322(8), 736–745. https://doi.org/10.1001/jama.2019.11889
• Lund-Nielsen, J., Vedel-Krogh, S., Kobylecki, C. J., Brynskov, J., Afzal, S., & Nordestgaard, B. G. (2018). Vitamin D and inflammatory bowel disease: Mendelian randomization analyses in the Copenhagen studies and UK Biobank. The Journal of Clinical Endocrinology and Metabolism, 103(9), 3267–3277. https://doi.org/10.1210/jc.2018-00250

Related reading

• Erectile Dysfunction Cardiovascular Risk: A Sentinel in Primary Care
• HLA-B27 and Ulcerative Colitis: Screening for Spinal Involvement
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.